Download Read Complete CV.

CURRICULUM VITAE
Eric L. Nuermberger, MD
Revised: December 28, 2007
DEMOGRAPHIC INFORMATION
Current Appointments:
University
Assistant Professor, Division of Infectious Diseases, Department
of Medicine, Johns Hopkins University School of Medicine
Hospital
The Johns Hopkins Hospital
Johns Hopkins Bayview Medical Center
Personal Data:
Office address
1550 Orleans St., Room 107
Baltimore, MD 21231
Tel: 410-502-0580
Fax: 410-614-8173
Email: [email protected]
Education and Training:
Undergraduate
Doctoral
Internship/
Residency
Fellowship
1992, B.S.
1996, M.D.
1996-1999
Kenyon College
Vanderbilt University
Johns Hopkins University
Psychology
Medicine
Internal Medicine
1999-2000
2001-2003
Johns Hopkins University
Infectious Diseases
Research mentors: Jacques Grosset, William Bishai
Professional Experience
2000-2001
2003-present
2004-present
Assistant Chief of Service, Department of Medicine, Johns
Hopkins University School of Medicine
Assistant Professor, Division of Infectious Diseases, Department
of Medicine, Johns Hopkins University School of Medicine
Assistant Professor, Department of International Health, Johns
Hopkins Bloomberg School of Public Health
1
RESEARCH ACTIVITIES - Publications
Peer-reviewed original research articles
1. Eustace JA, Nuermberger E, Choi M, Scheel PJ, Moore R, Briggs WA. Cohort study of the
treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int. 2000;58:125360.
2. Yoshimatsu T, Nuermberger E, Tyagi S, Chaisson R, Bishai W, Grosset J. Bactericidal
activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis.
Antimicrob Agents Chemother. 2002;46:1875-9.
3. Nuermberger E, Yoshimatsu T, Tyagi S, O’Brien RJ, Vernon AN, Chaisson RE, Bishai WR,
Grosset JH. Moxifloxacin-containing regimen greatly reduces time to culture conversion in
murine tuberculosis. Am J Respir Crit Care Med. 2004;169:421-6.
4. Nuermberger E, Yoshimatsu T, Tyagi S, Bishai WR, Grosset J. Paucibacillary tuberculosis in
mice after prior aerosol immunization with BCG. Infect Immun. 2004;72:1065-71.
5. Nuermberger EL, Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, O'Brien RJ, Vernon AA,
Chaisson RE, Bishai WR, Grosset JH. Moxifloxacin-containing regimens of reduced duration
produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med. 2004;170:1131-4.
6. Karakousis PC, Yoshimatsu T, Lamichhane G, Woolwine SC, Nuermberger EL, Grosset J,
Bishai WR. Dormancy Phenotype Displayed by Extracellular Mycobacterium tuberculosis
within Artificial Granulomas in Mice. J Exp Med. 2004;200:647-57.
7. Francis JS, Doherty MC, Lopatin U, Johnston CP, Sinha G, Ross T, Cai M, Hansel NN, Perl
T, Ticehurst JR, Carroll K, Thomas DL, Nuermberger E, Bartlett JG. Severe community-onset
pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the
Panton-Valentine leukocidin genes. Clin Infect Dis 2005; 40:100-7.
8. Yang S, Lin S, Khalil A, Gaydos C, Nuermberger E, Juan G, Hardick J, Bartlett JG,
Auwaerter PG, Rothman RE. Quantitative PCR assay using sputum samples for rapid diagnosis
of pneumococcal pneumonia in adult emergency department patients. J Clin Microbiol.
2005;43:3221-6.
9. Tyagi S, Nuermberger E, Yoshimatsu T, Williams K, Rosenthal I, Lounis N, Bishai W,
Grosset J. Bactericidal activity of the nitroimidazopyran, PA-824, in the murine model of
tuberculosis. Antimicrob Agents Chemother. 2005; 49:2289-93.
10. Rosenthal IM, Williams K, Tyagi S, Vernon AA, Peloquin CA, Bishai WR, Grosset JH,
Nuermberger EL. Weekly Moxifloxacin and Rifapentine is More Active than the Denver
Regimen in Murine Tuberculosis. Am J Respir Crit Care Med. 2005;172:1457-62.
2
11. Nuermberger E, Tyagi S, Williams K, Rosenthal I, Bishai WR, Grosset JH. Rifapentine,
Moxifloxacin or DNA Vaccine Improves Treatment of Latent Tuberculosis in a Mouse Model.
Am J Respir Crit Care Med. 2005;172:1452-6.
12. Nuermberger E, Helke K, Bishai WR. The Low-dose Aerosol Model of Pneumococcal
Pneumonia in the Mouse: Utility for Evaluation of Antimicrobial Efficacy. Int J Antimicrob
Agents 2005;26:497-503.
13. Rosenthal IM, Williams K, Tyagi S, Peloquin CA, Vernon AA, Bishai WR, Grosset JH,
Nuermberger EL. Potent Twice-weekly Rifapentine-containing Regimens in Murine
Tuberculosis. Am J Respir Crit Care Med. 2006; 2006;74:94-101.
14. Nuermberger E, Rosenthal I, Tyagi S, Williams KN, Almeida D, Peloquin CA, Bishai WR,
Grosset JH. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs
in the murine model of tuberculosis. Antimicrob Agents Chemother. 2006;50:2621-5.
15. Jain SK, Hernandez-Abanto SM, Cheng Q, Singh P, Ly LH, Morrison NE, Converse PJ,
Nuermberger E, Grosset J, McMurray DN, Karakousis PC, Lamichhane G, Bishai WR.
Accelerated detection of Mycobacterium tuberculosis genes essential for bacterial survival in
guinea pigs compared with mice. J Infect Dis. 2007;195:1634-42.
16. Chauty A, Ardant MF, Adeye A, Euverte H, Guedenon A, Johnson C, Aubry J,
Nuermberger E, Grosset J. Promising clinical efficacy of the combination streptomycin rifampin for the treatment of Buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents
Chemother. 2007;51:4029-35.
17. Byrne ST, Denkin SM, Gu P, Nuermberger E, Zhang Y. Activity of ketoconazole against
Mycobacterium tuberculosis in vitro and in the mouse model. J Med Microbiol. 2007;56:104751.
18. Rosenthal IM, Zhang M, Williams K, Peloquin CA, Tyagi S, Vernon AA, Bishai WR,
Chaisson RE, Grosset JH, Nuermberger EL. Daily dosing of rifapentine cures tuberculosis in
three months or less in the murine model. PLoS Medicine, 2007;4:e344 in press.
19. Almeida D, Nuermberger E, Tyagi S, Bishai WR, Grosset J. In vivo validation of the mutant
selection window hypothesis with moxifloxacin in a murine model of tuberculosis. Antimicrob
Agents Chemother. 2007;51:4261-6.
20. Converse PJ, Karakousis PC, Kesavan AK, Klinkenberg LG, Ly LH, Allen SS, Grosset JH,
Jain SK, Lamichhane G, Manabe YC, McMurray DN, Nuermberger EL, Bishai WR.
Comparative Animal Model Testing in Three Species Reveals that the Mycobacterium
tuberculosis dosR Gene is Required for Virulence. Microbiology, submitted.
21. Nuermberger E, Rosenthal I, Tyagi S, Williams KN, Almeida D, Rosenthal I, Bishai WR,
Grosset JH. A regimen containing PA-824 and moxifloxacin but without rifampin and isoniazid
3
is as active as first-line regimens the murine model of tuberculosis. Antimicrob Agents
Chemother, submitted.
EXTRAMURAL FUNDING
Current Grants
5/1/04 - 4/30/09: Moxifloxacin as a first-line TB drug
K08 AI 58993-01
NIH-NIAID
Total Direct Costs: $601,776
Principal Investigator: Nuermberger
1/1/06 – 12/31/07: Preclinical assessment of novel TB treatment regimens
Global Alliance for TB Drug Development
Total Direct Costs: $409,220
Principal Investigator: Nuermberger
9/1/06 – 1/31/08: Sequential approach to assess the potential role or oxazolidinones in
chemotherapy of tuberculosis using the lead compound PNU-100480
Pfizer
Total Direct Costs: $130,000
Principal Investigator: Nuermberger
11/1/07 – 10/31/09: Pharmacokinetics and pharmacodynamics of sterilizing activity across
experimental models
TB Drug Accelerator RFP
The Bill and Melinda Gates Foundation
Total Direct Cost: $1,799,257
Principal Investigator: Jacques H. Grosset
Role: Co-Principal Investigator
Current contracts
8/22/03 - 8/21/10: TB gene function in animal models
N01 AI 30036
NIH-NIAID-DMID
Total Direct Cost: $6,871,912
Principal Investigator: William R. Bishai
Role: Co-investigator
6/7/04 - 6/6/11: Pharmacokinetics and pharmacodynamics of antimicrobials in animal models
N01 AI 40007
NIH-NIAID-DAIDS
Total Direct Cost: $4,556,326
4
Principal Investigator: Jacques H. Grosset
Role: Co-Principal Investigator
Pending grants
1/1/08 – 12/31/09: Preclinical evaluation of new drug combinations against Mycobacterium
tuberculosis
Global Alliance for Tuberculosis Drug Development
Total Direct Cost: $1,107,778
Principal Investigator: Nuermberger
11/1/07 – 10/31/08: Pre-clinical Assessment of OPC-67683 in the Murine Model of TB
Otsuka Pharmaceuticals
Total Direct Cost: $139,091
Principal Investigator: Nuermberger
Previous grants
5/1/04 – 4/30/05: Rational design of improved intermittent drug regimens for treatment of TB
Potts Memorial Foundation
Total Direct Cost: $22,000
Principal Investigator: Nuermberger
12/1/04 – 8/31/06: In vivo efficacy of azithromycin for pneumococcal pneumonia using the
murine aerosol infection model
Independent Medical Study Grant #2004-0038
Pfizer
Total Direct Cost: $77,438
Principal Investigator: Nuermberger
11/1/05 – 10/31/06: Rational design of improved intermittent drug regimens for treatment of TB
Potts Memorial Foundation
Total Direct Cost: $25,000
Principal Investigator: Nuermberger
EDUCATIONAL ACTIVITIES
Educational Publications
Invited review articles
1. Nuermberger E. Current concepts in HIV-associated nephropathy. The Hopkins HIV Report
1999;11:12-4.
5
2. Nuermberger EL and Bishai WR. The clinical significance of macrolide-resistant
Streptococcus pneumoniae: It’s all relative. Clin Infect Dis. 2004;38:99-103.
3. Nuermberger E and Grosset J. Pharmacokinetic and pharmacodynamic issues in the
treatment of mycobacterial infections. Eur J Clin Microbiol Infect Dis. 2004;23:243-55.
4. Nuermberger E, Bishai WR, Grosset JH. Latent tuberculosis infection. Semin Resp Crit Care
Med. 2004;25:317-36.
5. Nuermberger E and Bishai WR. Antibiotic Resistance in Streptococcus pneumoniae: What
Does the Future Hold? Clin Infect Dis. 2004;38 Suppl 4:S363-71.
6. Nuermberger E. Current Issues in the Diagnosis, Evaluation, and Management of
Gastrointestinal Infections. Advanced Studies in Medicine 2005;5:297-304.
7. Zetola N, Francis JS, Nuermberger EL, Bishai WR. Community-acquired meticillin-resistant
Staphylococcus aureus: an emerging threat. Lancet Infect Dis. 2005;5:275-86.
8. Nuermberger E. Murine Models of Pneumococcal Pneumonia and their Applicability to the
Study of Tissue-Directed Antimicrobials. Pharmacotherapy 2005;25:134S-139S.
9. Davies GR and Nuermberger EL. Pharmacokinetics and pharmacodynamics in the
development of anti-tuberculosis drugs. Tuberculosis 2008; submitted.
Case Reports
1. Nuermberger E. Cases from the Osler Medical Service at Johns Hopkins University. Am J
Med. 2002;112:70-1.
2. Myers JS & Nuermberger E. Cases from the Osler Medical Service at Johns Hopkins
University. Am J Med. 2002;112:494-5.
3. Lanzkron S, Moliterno AR, Norris EJ, Gould SA, Segal J, Nuermberger EL, Ness PM.
Polymerized human hemoglobin use in acute chest syndrome: a case report. Transfusion
2002;42:1422-7.
Letters, correspondence
1. Nuermberger EL and Bishai WR. Significance of macrolide resistance in Streptococcus
pneumoniae. J Antimicrob Chemother. 2003;52:524-5.
2. Francis JS, Carroll K, Nuermberger E, Bartlett JG. Reply to Wargo and Eiland. Clin Infect
Dis. 2005;40:1378-9.
6
3. Davies GR, Pym AS, Mitchison DA, Nuermberger EL, Grosset JH. Evaluation of new
antituberculosis drugs in mouse models. Antimicrob Agent Chemother. 2007;51:403-4.
Book chapters
1. Nuermberger E & Bishai W. Management of community-acquired pneumonia caused by
drug-resistant Streptococcus pneumoniae. In: Management of Infections with Multiple Drug
Resistant Organisms, S.H. Gillespie (Ed.), Humana Press: Totowa, NJ, 2004, pp 3-30.
2. Ardehali H & Nuermberger E. Urinary Tract Infections. In: The Osler Medical Handbook,
A. Cheng & A. Zaas (Eds.), Mosby: Philadelphia, 2003, pp 735-43.
3. Nuermberger E & Grosset J. Pharmacokinetic and pharmacodynamic issues in the treatment
of mycobacterial infections. In: Antimicrobial Therapy and Vaccines II, 2nd edition, V.L. Yu et
al. (Eds.), Apple Trees Productions: New York, 2005, pp 391-404.
4. Passareti C, Ardehali H, Nuermberger E. Urinary Tract Infections. In: The Osler Medical
Handbook, 2nd edition, K.R. Nilsson & J.P. Piccini (Eds.), Saunders: Philadelphia, 2006, pp 66371.
5. Schiffer J & Nuermberger E. Tuberculosis. In: The Osler Medical Handbook, 2nd edition,
K.R. Nilsson & J.P. Piccini (Eds.), Saunders: Philadelphia, 2006, pp 640-7.
6. Nuermberger E. Acute Gastroenteritis and Associated Conditions. In: Principles of
Ambulatory Medicine, 7th edition, N.H. Fiebach et al (Eds.), Lippincott Williams & Wilkins:
Philadelphia, 2007, pp 513-27.
7. Nuermberger EL, Peloquin CA, Grosset JH. Pharmacological Issues in the Development of
New Antituberculosis Drugs. In: Development of New Antituberculosis Drugs, W.W. Yew
(Ed.), Nova Science Publishers: New York, 2007, pp 53-73.
8. Cheng Q, Bishai WR, Nuermberger EL. New developments in treatment. In: Clinical
Tuberculosis, P.D.O. Davies (Ed.), Chapman & Hall: London, in press.
Other media
1. Nuermberger E. Pneumococcal endocarditis and the Austrian syndrome: The clinical utility
of medical eponyms. Osler Medical Journal 1999;Volume 5, February, 1999. URL:
<http://omj.med.jhu.edu/casereports/vol5/Jan99.shtml>.
2. Johns Hopkins Antibiotic Guide: http://www.hopkins-abxguide.org
Current Author on sections/modules listed below:
Acute osteomyelitis, Chronic osteomyelitis, Acute septic arthritis, Lyme arthritis,
Prosthetic Joint Infection, Diabetic Foot Infection, Spinal Epidural Abscess
7
Former Author on sections: Antibiotic profiles, Bug/drug tables, Adverse effects
3. Johns Hopkins HIV Guide
Current Author on sections/modules listed below:
Bacterial Pneumonia, Streptococcus pneumoniae, Rhodococcus equi, HIVAssociated Nephropathy
Teaching
Classroom Instruction
2001, 2004-7 Pathophysiology, preceptor, microbiology case presentations, JHU SOM
2004-7
Pathophysiology, lecturer, Pneumonia, JHU SOM
2005-7
TB Today program, lecturer, Principles of TB Chemotherapy and Treatment,
Maryland Department of Health and Mental Hygiene
2006-7
TB Epidemiology, lecturer, New Drugs for TB, JHU Bloomberg School of Public
Health
2006-7
Pathophysiology, lecturer, Mycobacteria and Nocardia, JHU SOM
Clinical Instruction
2000-1
JHH Medical Grand Rounds, lecturer, Images of Osler
2000
JHH Internal Medicine Housestaff Conference, lecturer, Diabetic foot
infections
2000
JHH Internal Medicine Housestaff Conference, lecturer, Adrenal insufficiency
2001
JHH Internal Medicine Housestaff Conference, lecturer, Pneumocystis pneumonia
2001
JHH Internal Medicine Housestaff Conference, lecturer, Staphylococcus aureus
bacteremia
2004-7
JHH Internal Medicine Housestaff Conference, lecturer, Infective endocarditis
2005
JHH Clinicopathologic Conference, discussant
2006-7
JHH Pulmonary Didactic Conference, lecturer, Community-acquired pneumonia
2006-7
JHH Infectious Diseases Didactic Conference, lecturer, Infective endocarditis
CME Instruction
2001, 2007
Johns Hopkins Topics in Internal Medicine
May, 2001: Fever in a traveler
May, 2007: A case of Occam’s razor
2003-6
Johns Hopkins Topics in Infectious Diseases for Primary Care.
August, 2003: Lyme Disease, Gastrointestinal Infections
August, 2004: Staphylococcus aureus Infections, Urinary Tract Infections
August, 2005: Skin & Soft Tissue Infections Including, Urinary Tract Infections
August, 2006: Bone and Joint Infections, Urinary Tract Infections
2004-6
Internal Medicine Grand Rounds, Greater Baltimore Medical Center, Baltimore
8
March 11, 2004: Management of Staphylococcus aureus bacteremia
November 18, 2004: Updates on community-acquired MRSA infections and
urinary tract infections
January 20, 2005: New guidelines for community-acquired pneumonia,
Antibiotic Update: 2005
April 8, 2005: Managing Tuberculosis in 2005
April 20, 2006: What every resident should know about endocarditis
2005
Internal Medicine Grand Rounds, Riverside Hospital, Newport News, VA
January 12, 2005: Managing Tuberculosis in 2005
August 17, 2005: Community-associated MRSA Infections
2005
Johns Hopkins CME at Sea
July 2005: Skin & Soft Tissue Infections, Urinary Tract Infections, SexuallyTransmitted Diseases & HIV
2006
Filipino Medical Society of Eastern Virginia
March 2006: Appropriate use of antibiotics in respiratory tract infections
2007
Johns Hopkins POC-IT
May 2007: Role of the Physician in Pandemic Influenza
September 2007: Impact of Emerging Resistant Bacteria in the Hospital Setting
Mentoring
Thesis Advisor
Ian Rosenthal, Doctoral student
Rational Design of Improved Intermittent Drug Regimens
for the Treatment of Tuberculosis
Department of International Health, Bloomberg
School of Public Health, Johns Hopkins Univ.
NRSA F31 EB005094, NIH/NIBIB, Improved TB Drug
Delivery with Novel Polymeric Carriers
March, 2004 – January, 2007
Fellowship Advisor
John Francis, MD, Infectious Diseases Fellow (Co-advisor)
August, 2004 – June, 2006
Deepak Almeida, PhD, Post-doctoral Research Fellow
January, 2005 – present
Rokeya Tasneen, PhD, Post-doctoral Research Fellow
June, 2005 – present
Tianyu Zhang, PhD, Post-doctoral Research Fellow
September, 2005 – present
Ian Rosenthal, PhD, Post-doctoral Research Fellow
January, 2007 - present
Zahoor Ahmad Parry, PhD, Post-doctoral Research Fellow
9
April, 2007 - present
Thesis Committee
Member
Ian Rosenthal, Rational Design of Improved Intermittent
Drug Regimens for the Treatment of Tuberculosis,
Preliminary Doctoral Oral Exam, January 4, 2005
Ai Koyanagi, Double-blind randomized controlled trial of
nutritional supplementation to patients with sputum
smear positive tuberculosis in Ventanilla, Lima,
Preliminary Doctoral Oral Exam, Dec. 21, 2005
William Glover, Formation and Characterization of Cell
Wall Deficient Forms of Mycobacteria, Preliminary
Doctoral Oral Exam, September 12, 2006
CLINICAL ACTIVITIES
Certification
Licensure
State of Maryland (2000-present), #D0056070
Board certification
Internal Medicine, August 1999
Infectious Diseases, November 2002
Service responsibilities
Attending Physician, Infectious Diseases consult services, The Johns Hopkins Hospital
and Johns Hopkins Bayview Medical Center (5% Effort)
ORGANIZATIONAL ACTIVITIES
Institutional administrative appointments
Antibiotic Sub-committee, Pharmacy and Therapeutics Committee, Johns Hopkins
Hospital, January 2003-present
Curriculum Committee, Division of Infectious Diseases Fellowship Program, Department
of Medicine, Johns Hopkins University, 2004-present
Editorial Activities
Editorial Boards
Johns Hopkins POC-IT (2005-present)
Antimicrobial Agents and Chemotherapy (2008-11)
Section Editor
Infectious Diseases Section, Drug Discovery Today:
Disease Mechanisms, Volume 3, Issue 2, 2006.
10
Peer review activities
American Journal of Managed Care
American Journal of Medicine
American Journal of Resp. and Critical Care Medicine
Antimicrobial Agents and Chemotherapy
Archives of Internal Medicine
Canadian Medical Association Journal
Clinical Infectious Diseases
Expert Reviews of Anti-Infective Therapy
FEMS Microbiology Reviews
Infection
Infection and Immunity
International Journal of Infectious Diseases
International Journal of TB and Lung Disease
Journal of Antimicrobial Chemotherapy
Journal of Clinical Microbiology
Journal of Hospital Infection
Journal of Infection
Journal of Infectious Diseases
The Lancet
Medicine
Pharmacological Research
Transplant Infectious Diseases
Advisory committees, Review groups
Advisory committees
TB Expert Panel, Maryland Dept. of Health and Mental Hygiene, 2006-7
Review groups
NHLBI Special Emphasis Panel/Scientific Review Group 2005/05 ZHL1 CSR-G, K01 Grant
Reviewer, 3/21/2005-3/22/2005
Johns Hopkins Center for AIDS Research Pilot Grant Review Group, Reviewer, 4/2005
U.S. Civilian Research and Development Foundation Targeted Research Competition in
HIV/AIDS & Related Infections, Reviewer, 4/2005
NIAID Special Emphasis Panel ZAI1-QV-I-J1, U01 & R34 Grant Reviewer, 9/13/2006
Professional societies
Member
Alpha Omega Alpha (1996-2002)
Infectious Diseases Society of America (2000-present)
American Society for Microbiology (2004-present)
American Thoracic Society (2005-present)
Committees
American Thoracic Society Microbiology, Tuberculosis, and Pulmonary
Infections Program Committee, 2004-present
11
American Thoracic Society Representative, Stop TB Partnership Working
Group on New Drugs, 2006-present
Board of Directors Nominating Committee, Global Alliance Stakeholders
Association, 2007
Session chair
2005
2006
2007
Persistence: The Secret of Mycobacterium tuberculosis Success, Scientific
Symposium, American Thoracic Society Annual Meeting, San
Diego, May 22, 2005.
Managing Mycobacterial Infections, Poster Discussion Session, American
Thoracic Society Annual Meeting, San Diego, May 24, 2006.
Finding Solutions to XDR-Tuberculosis, Scientific Symposium, American
Thoracic Society Annual Meeting, San Francisco, May 21, 2007.
RECOGNITION
Awards, honors
CRC Chemistry Award, Kenyon College, 1989
Top Spear award in Physiology, Vanderbilt University School of Medicine, 1992
Alpha Omega Alpha, Vanderbilt University SOM, 1996
Rudolph H. Kampmeier Prize in Medicine, Vanderbilt University SOM, 1996
Merck Award for Excellence in Infectious Diseases, Vanderbilt University SOM, 1996
American Thoracic Society Travel Grant, 2003
ICAAC Program Committee Award, 2003
Clinical Infectious Diseases Award for Outstanding Review, 2005
Highlighted abstract, American Thoracic Society Annual Meeting, 2006
Highlighted abstract, American Thoracic Society Annual Meeting, 2007
Invited talks
Images of Osler. Medicine Grand Rounds. Johns Hopkins Hospital. Eight presentations between
9/00-6/01.
A novel mouse model of pneumococcal pneumonia used to evaluate the efficacy of ertapenem.
Oral presentation at the 42nd Interscience Conference on Antimicrobial Agents and
Chemotherapy, San Diego, September, 2002.
Assessment of moxifloxacin (MFX) activity at clinically relevant dosages in the mouse model of
tuberculosis (TB). Oral presentation at American Thoracic Society Annual Meeting, Seattle,
May, 2003.
The latest investigational data on moxifloxacin in the mouse. CDC Tuberculosis Trials
Consortium, 14th Semi-Annual Group Meeting, Atlanta, Oct. 21, 2003.
12
Improving the chemotherapy of TB: Insights from the mouse model. The Interurban Clinical
Club, Semiannual Meeting, Baltimore, Nov. 7, 2003.
The nitroimidazopyran PA-824 has promising activity in the mouse model of TB. Oral
presentation at American Thoracic Society Annual Meeting, Orlando, May 24, 2004.
Paucibacillary TB in the mouse. AERAS Global TB Vaccine Foundation, Post-infection Safety
of TB Vaccine Candidates Meeting, Washington, DC, June 11, 2004.
The low-dose aerosol model of pneumococcal pneumonia in the mouse. Pfizer Azithromycin
Pre-clinical Studies Scientific Meeting, New York, June 24, 2004.
Animal models of pneumococcal pneumonia: relevance for tissue-directed antibiotics. Scientific
Basis for Tissue-Directed Antimicrobial Therapy Meeting, Boston, July 22, 2004.
Shortening the duration of therapy of murine TB with moxifloxacin-containing regimens. Oral
presentation at International Union of Tuberculosis and Lung Diseases Annual Meeting, Paris,
October 30, 2004.
Role of moxifloxacin in tuberculosis chemotherapy. Symposium lecture at International Union
of Tuberculosis and Lung Diseases Annual Meeting, Paris, October 31, 2004.
Are we on the verge of a revolution in the treatment of TB? TB Special Interest Group Seminar,
Johns Hopkins University, January 25, 2005.
Shortening the Duration of Therapy of Murine TB with Moxifloxacin-containing Regimens. Oral
presentation at American Thoracic Society Annual Meeting, San Diego, May 22, 2005.
Performance of a Streptococcus pneumoniae Urinary Antigen Test in HIV-Infected Patients with
Community-Acquired Pneumonia. Oral presentation at American Thoracic Society Annual
Meeting, San Diego, May 22, 2005.
Mycobacterial and Human Genomics and Their Implications for Tuberculosis. Symposium
lecture at American Thoracic Society Annual Meeting, San Diego, May 24, 2005.
The nitroimidazopyran PA-824 increases the potency of the rifampin, moxifloxacin,
pyrazinamide (RMZ)-based regimen in the murine model of tuberculosis. Oral presentation at
International Union of Tuberculosis and Lung Diseases Annual Meeting, Paris, October, 2005.
New Chemotherapeutic Strategies for Tuberculosis. Symposium lecture at the 45th Interscience
Conference on Antimicrobial Agents and Chemotherapy, Washington DC, December 16, 2005.
The Next Revolution in TB Therapy: Insights from the Murine Model. Medicine Grand Rounds,
Johns Hopkins Hospital, Baltimore, January 6, 2006.
Rifapentine, moxifloxacin, mice and everything nice. CDC Tuberculosis Trials Consortium, 19th
Semi-Annual Group Meeting, San Diego, May 20, 2006.
13
New Drugs for MDR-TB. Symposium lecture at American Thoracic Society Annual Meeting,
San Diego, May 24, 2006.
New Drugs for TB Control. Tuberculosis, Maryland Department of Health and Mental Hygiene,
Division of TB, Refugee and Migrant Health Annual Meeting, September 14, 2006.
Dose-ranging Activity of Rifampin and Rifapentine in Combination with Moxifloxacin and
Pyrazinamide. CDC Tuberculosis Trials Consortium, 21st Semi-Annual Group Meeting, San
Francisco, May 19, 2007.
Comparative Activity of Escalating Doses of Rifapentine and Rifampin in the Mouse Model of
Tuberculosis. Oral presentation at the 47th Interscience Conference on Antimicrobial Agents and
Chemotherapy, Chicago, September 18, 2007.
New drugs for tuberculosis: What’s in the pipeline. Consortium to Respond Effectively to the
AIDS/Tuberculosis Epidemic (CREATE) Investigator’s Meeting, Rio de Janeiro, September 24,
2007.
14